Core Viewpoint - The article discusses the transformative impact of immersive technologies like VR and AI on healthcare, highlighting their potential to redefine health boundaries and address various medical conditions, thus opening up opportunities in the trillion-dollar silver economy [1][5]. Group 1: Immersive Therapy - Immersive therapy is being utilized for various treatments, including PTSD, addiction, and social training for children with autism, positioning VR and AR as "second-generation drugs" [8]. - Patients can gradually overcome psychological barriers in a safe environment through virtual scenarios and real-time AI adjustments [8][9]. Group 2: Aging and Health - By 2050, one in six people will be over 65, making brain health a critical investment topic, as longevity does not equate to sustained brain vitality [11]. - Sleep is identified as a key factor in maintaining brain health, with genetics serving as a reminder to focus on cognitive well-being [11]. Group 3: Opportunities in China - China possesses significant latecomer advantages in AI and medical technology, particularly in precision medicine and data application [14]. - The country is poised to rapidly advance in these fields, indicating a strong potential for growth and innovation [14]. Group 4: Digital Therapeutics - The FDA has established a new category for "software as a medical device," allowing doctors to prescribe software, indicating that digital therapies are becoming mainstream [17]. - Immersive medical applications are expected to enter a phase of large-scale implementation within the next 5-10 years [18].

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. has received approval for its initial public offering (IPO) of A-shares on the ChiNext board, with the issuance price set at RMB 7.05 per share [1][2]. Group 1: Issuance Details - The total number of shares to be issued is 63,193,277 shares, with a strategic placement involving both institutional and retail investors [2][3]. - The strategic placement will consist of 6,300,000 shares allocated to employee asset management plans, accounting for approximately 9.97% of the total issuance [3]. - The initial strategic placement was set at 12,638,655 shares (20.00% of total), but the final amount was adjusted to 9,478,992 shares (15.00%) due to a reallocation to offline issuance [3][4]. Group 2: Subscription and Allocation - The offline initial issuance quantity was 43,603,785 shares, representing 81.18% of the total issuance after deducting the final strategic placement [4]. - The online initial issuance quantity was 10,110,500 shares, accounting for 18.82% of the total issuance [4]. - The final subscription rate for the online issuance was 0.0198%, with a subscription multiple of 5,038.48 times [4]. Group 3: Payment and Lock-up Period - Investors must complete payment for their subscriptions by September 18, 2025, to ensure their allocations remain valid [5][6]. - Online issuance shares will have no restrictions on circulation, while offline shares will have a 10% lock-up period of 6 months [7]. - Strategic placement investors will face a 12-month lock-up period starting from the listing date [7][8].

１、网上投资者申购新股中签后，应根据本公告履行资金交收义务，确保其资金账户在２０２５年９月 １８日（Ｔ＋２日）日终有足额的新股认购资金，不足部分视为放弃认购，由此产生的后果及相关法律 责任由投资者自行承担。投资者款项划付需遵守投资者所在证券公司的相关规定。 网上投资者放弃认购的股份由保荐人（主承销商）包销。 登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 敬请投资者重点关注本次发行的缴款环节，并于２０２５年９月１８日（Ｔ＋２日）及时履行缴款义 务，具体内容如下： ２０２５年９月１８日 ■ 凡参与本次网上定价发行申购建发致新Ａ股股票的投资者持有的申购配号尾数与上述号码相同的，则为 中签号码。中签号码共有４１，７０７个，每个中签号码只能认购５００股建发致新Ａ股股票。 发行人：上海建发致新医疗科技集团股份有限公司 保荐人（主承销商）：中信证券股份有限公司 ２、本次发行的股票中，网上发行的股票无流通限制及限售期安排，自本次公开发行的股票在深圳证券 交易所上市之日起即可流通。 ４、网上投资者连续１２个月内累计出现３次中签后未足额缴款的情形时，自结算参与人最近一次申报 其放弃认购的次日起６个月（按１８０个自然 ...

一、网上申购情况 保荐人（主承销商）根据深交所提供的数据，对本次网上发行的申购情况进行了统计，本次网上发行有 效申购户数为 13,472,178 户，有效申购股数为 105,070,116,500 股，配号总数为 210,140,233 个，配号起 始号码为000000000001， 截止号码为000210140233。 根据《上海建发致新医疗科技集团股份有限公司首次公开发行股票并在创业 板上市发行公告》公布的 回拨机制，由于网上初步有效申购倍数为10,392.17808 倍，高于100倍，发行人和保荐人（主承销商） 决定启动回拨机制，将扣除最终 战略配售数量后本次公开发行股票数量的20%（向上取整至500股的整 数倍，即 10,743,000 股）由网下回拨至网上。 回拨后，网下最终发行数量为32,860,785股， 约占扣除最终战略配售数量后本次发行数量的 61.18%； 网上最终发行数量为 20,853,500 股，约占扣除最终战略配售数量后本次发行数量的38.82%。回拨后本 次网上发行的中签率为0.0198472227%，申购倍数为5,038.48834倍。 二、回拨机制实施、发行结构及网上发行中签 ...

Core Viewpoint - Recently, Chuangyue Huikang and Haiguang Information signed a strategic cooperation agreement to enhance their capabilities in the medical AI sector [1] Group 1: Strategic Partnership - Chuangyue Huikang's AI products have been adapted and optimized with Haiguang Information's DCU chips, creating a compatible and flexible computational platform [1] - The partnership aims to support the deployment and integration of Chuangyue Huikang's AI applications in the medical field [1] Group 2: Product Development - Chuangyue Huikang has launched dozens of medical AI products to date and plans to continue investing in research and development for public health AI applications, industry intelligent agents, and medical large models [1]

Core Insights - Pathological diagnosis is considered the "gold standard" for disease diagnosis but faces challenges such as complex data, a shortage of professionals, and inconsistent diagnostic standards [1] - SenseTime Medical utilizes a medical large language model "DaYi" as a central intelligence, integrating original pathological models and imaging models to create a "cross-specialty integration" technology system [1] - The company aims to provide systematic solutions to the challenges in the industry through efficient integration and collaborative understanding of pathological images, text reports, and clinical information [1] Company Developments - At the "11th Digital Pathology and Artificial Intelligence Academic Symposium," the CEO presented a report on the innovative paradigm of smart pathology driven by foundational models [1] - SenseTime Medical showcased the performance of its pathological large model, emphasizing the application value of artificial intelligence technology in real medical scenarios [1] - The company is developing a comprehensive "smart pathology" solution based on a multi-modal large model, achieving a closed-loop system through three major technology platforms [3] Future Directions - SenseTime Medical plans to continue exploring the intersection of digital pathology and artificial intelligence, focusing on overcoming key technologies of multi-modal large models [3] - The company aims to facilitate the transition of medical large models from "technically feasible" to "clinically useful" through a pathway of "model foundation - platform empowerment - ecosystem co-construction" [3]

Group 1 - The stock of Yidu Tech (02158.HK) increased by over 5% on September 24, reaching a rise of 5.39% to a price of 6.06 HKD [1] - The trading volume for Yidu Tech was reported at 74.9734 million HKD [1]

Core Viewpoint - Yidu Technology (02158) shares increased by over 5%, currently up 5.39% at HKD 6.06, with a trading volume of HKD 74.9734 million [1] Group 1: Company Developments - Yidu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - The company positions itself as a driver of AI medical transformation in China, leveraging its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] Group 2: Industry Impact - Yidu Technology's innovations enable high-efficiency and low-cost scalable applications of AI technology, facilitating intelligent decision-making across the entire healthcare ecosystem, including "medicine-insurance-patients" [1]

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.06 HKD with a transaction volume of 74.9734 million HKD, following the announcement of a significant project win [1] Company Summary - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - The company positions itself as a driver of AI transformation in healthcare, utilizing its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] - This system enables efficient innovation and low-cost scalable applications of AI technology, empowering intelligent decision-making across the entire healthcare ecosystem, including medicine, insurance, and patients [1]

9月23日，2025中外知名企业四川行活动（以下简称四川行活动）在成都开幕。活动现场，两组数据引起记者 的注意：14——纳入主体活动现场集中签约项目共14个，投资金额359亿元，且全部为新质生产力项目；70%—— 参会企业中，产业背景与四川着力构建的"15+N"重点产业链方向高度契合的企业占比超70%。 两组数据清晰指向本次四川行活动的目标：大力引进发展新质生产力的前沿项目，扎实推进重点产业建圈强 链。 引入项目 主打新兴和未来 "今年签约落地的项目不少属于新兴产业和未来产业。"开幕式结束后，多位参会企业代表表达了相同的观 察。记者了解到，此次四川行活动期间，拟签约投资合作项目340个，投资金额2630.6亿元。其中，四川六大优势 产业项目占比超80%，新兴产业和未来产业项目占比达39%。 具身智能人形机器人制造总部基地、北京推想AI车载流动医疗西部总部及生产基地、集成电路核心设备生产 研发基地……记者梳理开幕式现场集中签约的14个代表性项目后，有一个直观的感受：向"新"力满满。 落地自贡的北京推想AI车载流动医疗西部总部及生产基地便是代表之一。"四川拥有丰富的医疗资源。我们希 望通过AI车载流动医疗装备，将 ...